Evidence increasingly suggests that glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs), widely used for the treatment of type 2 diabetes, may also be used as cardio- or neuroprotectants (Salcedo et al., 2012; Gault and Hölscher, 2018). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.